Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

J&J's Zytiga meets in Phase III LATITUDE trial for hormone-naïve prostate cancer

June 16, 2017 9:28 PM UTC

Johnson & Johnson (NYSE:JNJ) reported data from the Phase III LATITUDE trial in 1,199 patients with newly diagnosed, high-risk metastatic hormone-naïve prostate cancer showing that Zytiga abiraterone acetate (CB7630) plus androgen deprivation therapy met the co-primary endpoints of improving overall survival (OS) and radiographic progression-free survival (PFS) vs. placebo plus androgen deprivation therapy at a median follow-up of 30.4 months. Specifically, median OS was not reached in the Zytiga plus androgen deprivation therapy arm vs. 34.7 months for placebo plus androgen deprivation therapy (HR=0.62, 95% CI: 0.51, 0.76, p<0.001). Additionally, Zytiga plus androgen deprivation therapy led to a median radiographic PFS of 33 months vs. 14.8 months for placebo plus androgen deprivation therapy (HR=0.47, 95% CI: 0.39, 0.55, p<0.001).

Zytiga plus androgen deprivation therapy also met the secondary endpoints of improving time to pain progression, next subsequent therapy for prostate cancer, initiation of chemotherapy, prostate-specific antigen (PSA; KLK3) progression (p<0.0001 for all) and next symptomatic skeletal-related event (p=0.0086) vs. placebo plus androgen deprivation therapy. Data were presented at the American Society of Clinical Oncology meeting in Chicago and published in the New England Journal of Medicine...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article